William Blair has initiated coverage on Viridian Therapeutics Inc (VRDN) with an Outperform rating. This marks the firm's first assessment of the biotechnology company, which is based in Waltham, Massachusetts and specializes in developing proprietary RNA-targeted therapeutics. Currently, Viridian Therapeutics is advancing multiple candidates for the treatment of thyroid eye disease (TED), including veligrotug, a humanized monoclonal antibody targeting IGF-1R.
The firm is conducting two global Phase 3 clinical trials, THRIVE and THRIVE-2, to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. Additionally, Viridian is engaged in two global Phase 3 trials, REVEAL-1 and REVEAL-2, to assess the efficacy and safety of VRDN-003.
As of December 2, 2025, VRDN's shares are trading at $32.26, with a market capitalization of approximately $2.9 billion. The company has reported a trailing twelve-month EPS of -3.72. Upcoming earnings are anticipated on August 4, 2026, with an estimated EPS of -1.11 and revenue of $25.6 million.
Analyst ratings, such as this one from William Blair, provide insights based on research and financial models. However, they are subject to change as new information emerges, and investors should consider a range of factors, including company fundamentals and industry trends, when making investment decisions.